What is it?
The mCannabis.RealWorld Program is a novel enabling mechanism to address urgent clinical or policy knowledge gaps related to the efficacy and safety of cannabis in a real-world setting. The current approach supports post-market (i.e., after regulatory approval) studies using real-world data and builds on the success of the Exploring Cannabis-Based Medicines and Tools (mCannabis) Program. Real-world data are sources of information collected outside of conventional randomized clinical trials. This type of information can provide evidence about the health outcomes of diverse patient populations in a real-world setting and provide important economic insights to inform clinical or policy decisions.
The figure below outlines a typical drug development process and how AB Innovates’ strategy for addressing knowledge gaps.
The table below contains details of three leading Alberta-based researchers and their projects aiming to address urgent clinical or policy knowledge gaps related to cannabis use.
Bo Cao, PhD, UAlberta
Predicting the risk of opioid misuses in patients using cannabis-based medicine and opioids
Cheryl Sadowski, PharmD, UAlberta
Cannabis Use in Rheumatology Patients
Suzette Brémault-Phillips, PhD, UAlberta
Understanding Medical Value and Risks for Veterans: Medicinal and Recreational Cannabis Use
- Total value for all three projects is ~ $930,000 with ~ $900,000 (97%) contributed from Alberta Innovates.
- Six (6) applications were received. Three (3) applications were selected for funding.
- Applications were peer-reviewed through a two-stage evaluation process.
- Applicants were provided a unique opportunity to engage with a panel of 12 partners representing industry, academia, clinicians, research facilitators, and other health care agents to strengthen full proposals as well as identify collaborative opportunities. Six new collaborations resulted from 5 strengthening partners.
- Projects will run from March 2021 to March 2023.
The mCannabis.RealWorld Program is the first of its kind.
A unique feature of the mCannabis.RealWorld Program is an opportunity to engage with a panel of industry members, academics, clinicians, research facilitators, and other health care agents to strengthen full proposals as well as identify collaborative opportunities.
Current members and data resources (supplied by volunteer panel members) are found in the table below.
|Member||Role & Affiliation||Data Resources|
|David Berg||President & CTO, Strainprint||Data Dictionary
|Don Reynolds||Director, Headset||Market sales data dictionary|
||CEO, Reformulary Group
||Cannabis-related data description
Drug claims data dictionary
|Kit Poon||Director, ARBR||Literature-based data dictionary|
|Michael Colbourne||CEO, Neobi||Market sales data dictionary|
|CEO, Inagene Diagnostics
VP, Sales and Marketing, Inagene Diagnostics
|Pharmacogenetics data summary|
|Dr. Jeremy Beach
|Assistant Registrar, Physician Health Monitoring Program, College of Physicians and Surgeons of Alberta
Chief Innovation and Analytics Officer, College of Physicians and Surgeons of Alberta
|Dr. Robert Tanguay||President, Pain Society of Alberta||Commonly used, clinically validated questionnaires|
|Dr. Finlay McAlister
Dr. Hude Quan
Dr. Maria Santana
|Lead, Data Platforms, Alberta Strategy for Patient Oriented Research SUPPORT Unit (AbSPORU)
Lead, Methods Development, (AbSPORU)
Lead, Patient Engagement, (AbSPORU)
|Alberta Health Data Asset Directory (2018)
Alberta admin datasets (2017)
Link to top seven databases
|Dr. Lawrence Richer
Dr. Scott Klarenbach
|Director, Northern Alberta Clinical Trials & Research Centre (NACTRC)
Director, NACTRC Real World Evidence Unit
|Dr. Sana-Ara Ahmed||Anesthesiologist, Pain & Cannabinoids Specialist, Genuvis Health|
|Dr. Luisa Barton||Nurse Practictioner & Clinical Manager, Athabasca University||Sample of cannabis consult intake form
Sample of initial medical cannabis consult note
Applicants who participate in mCannabis.RealWorld can expect the following outcomes:
- Generate real-world evidence to inform clinical or policy decisions.
- Build collaborative connections within the health innovation ecosystem.
- Improve Canadian competitiveness in the global cannabis sector.
- Enable rapid knowledge generation using digital health strategies.
- Create accessible new data sources related to medical cannabis use.
- Enhance patient-centred care.
- Projects led by post-secondary institutions, not-for-profit corporations, or health delivery agent in Alberta.
- Must address a clearly defined and major clinical or policy problem, need, or critical barrier that has relevance to Alberta.
- Seek to generate new data, analyze data relationships, or curate real-world data to support the problem.
- See program guide for full details.
Alberta Innovates will contribute up to $300,000 CAD to support approved projects over a maximum term of 24 months. Successful Expression of Interest applicants will be eligible to receive up to $10,000 CAD to support proposal development.
Important dates – Apply now!
- Expression of Interest (Stage 1) deadline: October 7th, 2020 at 4:00 PM MST
- EOI decision: Early November 2020
- Strengthening Panel dates: 23 and 26 November 2020 (Expected)
- Full Proposal (Stage 2) deadline: December 16th, 2020 at 4:00 PM MST
- Full Proposal Decision: February 2021
- Agreement: March 2021
- Expression of Interest (Stage 1) Application (please consider the data resources in the table above).
- Successful EOI Applicants present at strengthening panel session.
- Advance to Full Proposal (Stage 2) Application.
Please note that you will need to create an account to access our online application portal. If you have any questions about the application process or concerns about your project’s eligibility, feel free to contact Alberta Innovates at any time.